The Incyte FGFR1/2/3 kinase inhibitor, pemigatinib , is an oral kinase inhibitor that obtained an FDA accelerated approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangement as detected by an FDA-approved test. There were no [...]
1 minute read
Dec. 16, 2021
Pemigatinib: a FGFR1/2/3 Kinase Inhibitor
pemigatinib
oral FGFR1/2/3 kinase inhibitor approved in oncology, 13.5 mg QD (14d+, 7d-) from focused screen of ~20k cmpds and SBDD Journal of Medicinal Chemistry Incyte Corporation, Wilmington, US